Lunai Bioworks partners with Tanaist to enhance Parkinson's disease research using human cellular validation.

Lunai Bioworks has announced an exclusive worldwide license and collaboration with Tanaist to integrate human cellular phenotyping into its AI-driven Parkinson's disease platform. This partnership aims to validate patient subtypes identified by Lunai's AI tools by connecting them to biological mechanisms and biomarkers. The collaboration will strengthen Lunai's efforts to translate AI discoveries into effective treatments for Parkinson's disease.